The global hemodialysis and peritoneal dialysis market, valued at $92.0 billion in 2024, is projected to reach $126.2 billion by 2029, growing at a CAGR of 6.5%. This growth is driven by the rising prevalence of chronic kidney disease (CKD), particularly due to aging populations and increasing rates of diabetes and hypertension. Technological advancements, patient preference for home dialysis, and supportive reimbursement policies are key factors boosting market demand. However, complications linked to dialysis procedures and product recalls pose challenges. The market offers significant opportunities in emerging regions like China, India, and Brazil, where healthcare spending is increasing. Key players include Fresenius Medical Care, Baxter International, and DaVita Inc., and recent developments such as acquisitions and partnerships are enhancing market capabilities. North America is expected to maintain the largest market share due to its advanced healthcare infrastructure and growing adoption of home-based dialysis.
Hemodialysis and Peritoneal Dialysis Market Dynamics
Driver: Rising prevalence of chronic kidney disease globally
The rising prevalence of chronic kidney disease (CKD) globally is expected to significantly drive the hemodialysis and peritoneal dialysis market. Chronic kidney disease is likely to affect more than 10% of the population worldwide as chronic kidney disease becomes more prevalent due to factors such as aging populations, increasing rates of diabetes and hypertension, increasing the CKD progression to end-stage renal diseases, necessitating the dialysis. Chronic kidney disease (CKD) is more prevalent among individuals aged 65 years or older. According to Centres of Disease Control and Prevention (CDC), an estimated 35.5 million people in US were diagnosed with CKD in 2023.
Restraint: Complications linked with dialysis procedures
Dialysis, an essential renal replacement therapy for patients with end-stage renal disease, is associated with risks and complications. ESRD patients undergoing treatment are more susceptible to infections ranging from bloodstream infections to access site infections. Infectious and non-infectious vascular access complications are common and associated with increased morbidity, mortality, high costs, and reduced quality of life in dialysis patients. ESRD patients who choose HD require vascular access (catheters, grafts, and fistulae), and those who choose PD require a peritoneal catheter before initiation of RRT. The type of vascular access used in HD patients significantly influences patient survival due to associated complications. Compared with grafts and fistulae, catheters are associated with a substantially greater risk of sepsis, hospitalization, and mortality in HD patients. These associated risks and complications negatively affect the adoption of dialysis treatment among ESRD patients, thereby hampering the growth of the dialysis market.
Opportunity: High growth potential of emerging markets
Emerging markets such as China, India, Brazil, are expected to offer significant growth opportunities for players operating in the POC diagnostics market. This is primarily due to the high and growing prevalence of diabetes, chronic kidney diseases, in these countries. As economic growth in China and India continues to expand, there is rise in healthcare spending across these countries, which leads to improved affordability of hemodialysis and peritoneal dialysis treatment. According to the article published by BMC Nephrology in 2023, in China, the prevalence of ESRD is projected to reach 1,505 patients per million population by 2025. To meet the increasing demand for dialysis in the emerging markets, players focus on acquiring or entering into agreements and partnerships with healthcare providers.
Moreover, the rise in number of dialysis clinics in emerging countries can present a significant opportunity for hemodialysis and peritoneal dialysis market growth. Moreover initiatives undertaken by government to improve the access to healthcare services, including dialysis, across emerging nations through investment in healthcare infrastructure, subsidizing treatment costs are likely to enhance the market growth opportunities. Government of India has implemented Pradhan Mantri National Dialysis Programme (PMNDP) that offers free-of-cost dialysis services to Below Poverty Line (BPL) beneficiaries at district hospitals across the country. As of 31st December 2022, around 1.7 million beneficiaries availed of Haemodialysis and Peritoneal Dialysis services under PMNDP.
Challenge: Product Recall
The dialysis market has witnessed several recalls in the last few years due to health hazards related to their use and regulatory non-compliance. For instance
- In 2023, Baxter Healthcare Corporation has recalled almost 280,000 bags of Dianeal peritoneal dialysis solution due to sterility concerns over potential leaks, according to the US Food and Drug Administration (FDA)
- In 2023, Fresenius Medical Care recalled several hemodialysis machines for potential exposure to toxic compounds such as non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) that leak from some peroxide-cured silicone tubing used as part of the hydraulics in the machine and dialysate lines.
Recalls of dialysis devices place a significant financial burden on manufacturing firms due to costs to implement the recall, costs involved in product replacement, and the downturn in sales during a period of uncertainty. This, in turn, negatively affects the product scope, adoption, sales, growth prospects, and the capital structure of the manufacturing firm.
The hemodialysis services to capture the largest market share of hemodialysis and peritoneal dialysis industry.
Based on the hemodialysis products and services market, the hemodialysis services segment holds the largest hemodialysis and peritoneal dialysis market share owing to growing number of ESRD patients and increasing utilization of hemodialysis treatment modality. Moreover, hemodialysis services are focusing on expanding their services offerings by launching and acquiring new dialysis centers across the globe. In January 2024, Diaverum, a Sweden based renal care service provider, acquired a network of six dialysis clinics across Greece, thus enhancing its customer base across the country.
By End User, home care settings to grow at a significant rate from 2024-2029 of hemodialysis and peritoneal dialysis industry.
Based on end users, home care setting is expected to grow at a significant rate owing to growing preference of patients for home hemodialysis modality, technological advancements, and the cost-effectiveness of home dialysis treatment over incentre dialysis procedures.
North America to account for the largest share of hemodialysis and peritoneal dialysis industry during the forecast period.
North America is expected to be the largest regional market for hemodialysis and peritoneal dialysis market during the forecast period. The presence of a well-established healthcare system, rapid increase in the availability of medical reimbursement for dialysis procedures, growing adoption of home-based dialysis modality, increasing prevalence of end-stage renal diseases across the nation, and strong geographical footprint of dialysis product manufacturers and service provider focusing on collaboration with renal care institutions are likely to support the hemodialysis and peritoneal dialysis market growth across the region.
As of 2023, prominent players in global hemodialysis and peritoneal dialysis market include Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International, Inc. (US), Nikkiso Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), DaVita Inc. (US), Nipro Corporation (Japan), Diaverum (Germany), Medtronic plc (Ireland), Rockwell Medical, Inc. (US), Becton, Dickinson and Company (US), Dialife SA (Switzerland), and Isopure Corp. (US).
Recent Developments of Hemodialysis and Peritoneal Dialysis Industry:
- In July 2023, Rockwell Medical acquired the hemodialysis concentrates business from Evoqua Water Technologies, strengthening its presence in the hemodialysis market
- In January 2022, Nextkidney BV acquired Dialyss Pte Ltd, enhancing its technology capabilities in home hemodialysis
- In March 2021, DaVita Inc. signed an agreement with Fresenius Medical Care AG & Co. KGaA for the expansion of the usage of NxStage Home Hemodialysis Machines
